Daiichi Sankyo Co., Ltd. was formed in 2005 through a corporate merger between Sankyo Company, Ltd. and Daiichi Pharmaceuticals in order to create a company that pursued groundbreaking pharmaceutical research and development. Ranbaxy Laboratories Limited, from India, became a subsidiary of Daiichi Sankyo in June 2008, and assisted Daiichi Sankyo's full-blown entry into the late-stage pharmaceuticals market. Takashi Shoda, the company’s President and CEO at the time, defined this as a hybrid business model and decided on a plan to increase the company’s presence in the Japanese, European and American pharmaceutical markets. Both innovative and established drugs served as focal points for business development. The company aims to achieve the goals and realize the vision for 2015 set forth by President Kajino of the Daiichi Sankyo Group. The company strives for sustainable growth as dictated by market forecasts. This case study additionally examines Daiichi Sankyo’s products and its related businesses. The company is currently developing four product areas: innovative drugs, established drugs, vaccines, and Over-the-counter drugs. The company aggressively markets its products worldwide. President Kajino constantly contemplates business and marketing strategies. He reflects on the varying market potential of his company's products and develops comparative evaluations of business models.